Investigations of the vascular endothelial factor levels’ changes in experimental diabetic retinopathy
DOI:
https://doi.org/10.12775/JEHS.2022.12.04.034Keywords
experimental diabetic retinopathy, experimental diabetes, vascular growth factor, pathogenetic correctionAbstract
Introduction: The paper presents the results of the vascular endothelial growth factor of rats with experimental diabetic retinopathy (DR).
Material and methods: Experimental studies were performed on white Wistar rats, which were divided into 7 groups: 1st group – intact animals; 2nd group – 60 animals with modelling of DR without correction (control pathology); 3rd group –60 animals with modelling of DR with correction of hyperglycemia; 4th group – 60 animals with modelling of DR with correction of hyperglycemia, administration of aflibercept and L-arginine solution; 5th group – 60 animals with modelling of DR with correction of hyperglycemia, administration of aflibercept and bromfenak; 6th group – 60 animals with modelling of DR with correction of hyperglycemia, administration of aflibercept, L-carnitine solution and bromfenak; 7th group – 60 animals with modelling of DR with correction of hyperglycemia, administration of aflibercept, L-arginine solution and citicoline.
Results: The results of the analysis of the VEGF in the 2nd group confirm the development of DR, a particularly pronounced increase in the marker was detected on the 180th day of the development of the pathological process. The results of the 4th group indicate that the involvement of a nitric oxide donor and aflibercept in the correction of DR has positive effect on the reduction of the VEGF level, more pronounced compared to the 3rd group, but it does not reach normative values. It is observed that the correction of the simulated pathological condition by reducing hyperglycemia, administration of aflibercept and bromfenac (group No. 5) gives positive results, but less pronounced, compared to the data of the 4th group. It was found that in rats with DR with subsequent correction of hyperglycemia, administration of aflibercept, L-carnitine and bromfenac (group No. 6) at the first stage, there is a pronounced effectiveness of the proposed method of correction in comparison with the previously considered methods. The most pronounced positive effect of normalizing the VEGF level is observed when using a hypoglycemic drug in combination with the administration of aflibercept, a solution of L-arginine and citicoline (group No. 7).
Conclusions: The obtained data confirm the development of diabetic retinopathy, a particularly marked increase in the marker was detected on the 180th day of the development of the pathological process (p<0.001). Aflibercept has a positive effect on the normalization of this condition, but a more pronounced effect is observed in combination with long-term administration of L-arginine. The relationship between the normalization of the vascular growth factor and the correction of hypoxia was also revealed.
References
Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021 Aug;12(8):1322-1325. doi: 10.1111/jdi.13480. Epub 2021 Jan 14. PMID: 33316144; PMCID: PMC8354492.
Tan TE, Wong TY. Diabetic retinopathy: Looking forward to 2030. Front Endocrinol (Lausanne). 2023 Jan 9;13:1077669. doi: 10.3389/fendo.2022.1077669. PMID: 36699020; PMCID: PMC9868457.
Simó-Servat O, Hernández C, Simó R. Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Res. 2019;62(4):211-217. doi: 10.1159/000499541. Epub 2019 May 24. PMID: 31129667.
Sirman Ya. V., Preys N. I., Savitsky I. V., Badiuk N. S., Blavatska O. M, Hrytsan I. I., Tsypoviaz S. V. Dynamics of vasoconstructor-vasodilation potential on the background of the development of experimental diabetic retinopathy / PharmacologyOnLine; Archives - 2021 - vol.1 – 90-95.
Yin L, Zhang D, Ren Q, Su X, Sun Z. Prevalence and risk factors of diabetic retinopathy in diabetic patients: A community based cross-sectional study. Medicine (Baltimore). 2020 Feb;99(9):e19236. doi: 10.1097/MD.0000000000019236. PMID: 32118727; PMCID: PMC7478682.
Ghamdi AHA. Clinical Predictors of Diabetic Retinopathy Progression; A Systematic Review. Curr Diabetes Rev. 2020;16(3):242-247. doi: 10.2174/1573399815666190215120435. PMID: 30767747.
Arrigo A, Aragona E, Bandello F. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Ann Med. 2022 Dec;54(1):1089-1111. doi: 10.1080/07853890.2022.2064541. PMID: 35451900; PMCID: PMC9891228.
Yang J, Liu Z. Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. Front Endocrinol (Lausanne). 2022 May 25;13:816400. doi: 10.3389/fendo.2022.816400. PMID: 35692405; PMCID: PMC9174994.
Niklander S, Bordagaray MJ, Fernández A, Hernández M. Vascular Endothelial Growth Factor: A Translational View in Oral Non-Communicable Diseases. Biomolecules. 2021 Jan 12;11(1):85. doi: 10.3390/biom11010085. PMID: 33445558; PMCID: PMC7826734.
Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020 Oct;37:101799. doi: 10.1016/j.redox.2020.101799. Epub 2020 Nov 13. PMID: 33248932; PMCID: PMC7767789.
Spencer BG, Estevez JJ, Liu E, Craig JE, Finnie JW. Pericytes, inflammation, and diabetic retinopathy. Inflammopharmacology. 2020 Jun;28(3):697-709. doi: 10.1007/s10787-019-00647-9. Epub 2019 Oct 14. PMID: 31612299.
Yue T, Shi Y, Luo S, Weng J, Wu Y, Zheng X. The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Front Immunol. 2022 Dec 13;13:1055087. doi: 10.3389/fimmu.2022.1055087. PMID: 36582230; PMCID: PMC9792618.
Forrester JV, Kuffova L, Delibegovic M. The Role of Inflammation in Diabetic Retinopathy. Front Immunol. 2020 Nov 6;11:583687. doi: 10.3389/fimmu.2020.583687. PMID: 33240272; PMCID: PMC7677305.
Kaštelan S, Orešković I, Bišćan F, Kaštelan H, Gverović Antunica A. Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem Med (Zagreb). 2020 Oct 15;30(3):030502. doi: 10.11613/BM.2020.030502. Epub 2020 Aug 5. PMID: 32774120; PMCID: PMC7394255.
LAW OF UKRAINE. On the protection of animals from cruelty. https:// zakon.rada.gov.ua/laws/show/3447-15. (12.08.2021).
Reznikov OG, Solovyov AI, Stefanov OV. Biotic examination of reports and sciences of science, how to win on creatures: method. recommendations. Bulletin of Pharmacology and Pharmacy. 2006; 7: 47–61.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Nataliya Preys, Ivan Savytskyi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 29
Number of citations: 0